Literature DB >> 21676622

Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.

Sven Otto1, Christian Schreyer, Sigurd Hafner, Gerson Mast, Michael Ehrenfeld, Stephen Stürzenbaum, Christoph Pautke.   

Abstract

INTRODUCTION: Osteonecrosis of the jaw (ONJ) is a serious side-effect of intravenous nitrogen-containing bisphosphonate therapy frequently used in the treatment of malignant diseases. Despite numerous case series published so far studies with detailed investigations into risk factors, the precise localization of ONJ and impact of ONJ on the oncological treatment remain sparse. PATIENTS AND METHODS: This single-centre study collated medical records (2003-2009) of all patients that suffered from ONJ within the Department of Oral and Maxillofacial Surgery, Ludwig-Maximilians-University of Munich, Germany. In total, 126 patients fulfilled the case criteria of ONJ and were examined clinically. The complete medical history including detailed questionnaires was collected of 66 patients, focussing in particular on the identification of underlying risk factors, clinical features, ONJ localization as well as the impact on the oncological treatment.
RESULTS: The majority of ONJ cases occurred in patients suffering from malignant diseases (n=117; 92.8%), in particular breast cancer (n=57; 45.2%), multiple myeloma (n=37; 29.4%) and prostate cancer (n=13; 10.3%), all received nitrogen-containing bisphosphonates intravenously. ONJ was also diagnosed in 9 patients (7.1%) suffering from osteoporosis or rheumatoid arthritis. The most prevalent clinical feature was exposed necrotic bone (93.9%) in the oral cavity which was accompanied in 78.8% of cases by pain. A predilection for the mandible and in particular for molar and premolar regions in both jaws was shown. Although no recommendation concerning the oncologic treatment was made, the manifestation of ONJ resulted (in a significant proportion of the patients) in a change of medication and schedule. The most frequent co-medications were steroids and anti-angiogenetic drugs, such as thalidomide. DISCUSSION: The predilection for mandibular molar and premolar regions, and the infectious conditions that often precede the onset of ONJ support recent pathogenesis theories stating that local inflammation and associated pH-changes may trigger the release and activation of nitrogen-containing bisphosphonates ultimately resulting in necrosis.
CONCLUSION: The development of ONJ has a multi-factorial aetiology and the clinical presentation can vary markedly. ONJ cannot only impair the quality of life but also the treatment of the underlying disease.
Copyright © 2011 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21676622     DOI: 10.1016/j.jcms.2011.05.003

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  49 in total

1.  Intraoperative detection of viable bone with fluorescence imaging using Visually Enhanced Lesion Scope in patients with bisphosphonate-related osteonecrosis of the jaw: clinical and pathological evaluation.

Authors:  D Yoshiga; M Sasaguri; K Matsuo; S Kokuryou; M Habu; M Oda; M Kodama; H Tsurushima; O Sakaguchi; T Sakurai; J Tanaka; Y Morimoto; I Yoshioka; K Tominaga
Journal:  Osteoporos Int       Date:  2015-06-03       Impact factor: 4.507

2.  Legal liability in bisphosphonate-related osteonecrosis of the jaw.

Authors:  L Lo Russo; D Ciavarella; C Buccelli; O Di Fede; G Campisi; L Lo Muzio; G Pellegrino; P Di Lorenzo
Journal:  Br Dent J       Date:  2014-09       Impact factor: 1.626

3.  Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw.

Authors:  Paula Baptistella de Lima; Veruska Lima Moura Brasil; Jurema Freire Lisboa de Castro; Flávia Maria de Moraes Ramos-Perez; Fábio Abreu Alves; Maria Luiza dos Anjos Pontual; Danyel Elias da Cruz Perez
Journal:  Support Care Cancer       Date:  2015-03-11       Impact factor: 3.603

4.  Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease.

Authors:  Akrivoula Soundia; Danny Hadaya; Navid Esfandi; Rafael Scaf de Molon; Olga Bezouglaia; Sarah M Dry; Flavia Q Pirih; Tara Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2016-06-18       Impact factor: 4.398

5.  Influence of pH on osteoclasts treated with zoledronate and alendronate.

Authors:  Francisco Javier Manzano-Moreno; Javier Ramos-Torrecillas; Elvira de Luna-Bertos; Rebeca Illescas-Montes; Timothy R Arnett; Concepción Ruiz; Olga García-Martínez
Journal:  Clin Oral Investig       Date:  2018-06-06       Impact factor: 3.573

6.  The multiple oral presentations of multiple myeloma.

Authors:  Richard C Cardoso; Peter J Gerngross; Theresa M Hofstede; Donna M Weber; Mark S Chambers
Journal:  Support Care Cancer       Date:  2013-09-20       Impact factor: 3.603

7.  Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases.

Authors:  Annalisa Bramati; Serena Girelli; Gabriella Farina; Maria Chiara Dazzani; Valter Torri; Anna Moretti; Sheila Piva; Mariastella Dimaiuta; Nicla La Verde
Journal:  J Bone Miner Metab       Date:  2014-02-20       Impact factor: 2.626

8.  The Effectiveness of the Low-Level Laser, Antibiotic and Surgical Therapy in the Treatment of Medication-Related Osteonecrosis of the Jaws: A Case Report.

Authors:  Maria Del Pilar Rodríguez-Sánchez; Cristian Statkievicz; João Martins de Mello-Neto; Luan Felipe Toro; Ana Paula Farnezzi Bassi; Valdir Gouveia Garcia; Letícia Helena Theodoro; Edilson Ervolino
Journal:  J Lasers Med Sci       Date:  2020-01-18

9.  Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab.

Authors:  Daria Pakosch; Dimitrios Papadimas; Johanna Munding; Darafsch Kawa; Marcus Stephan Kriwalsky
Journal:  Oral Maxillofac Surg       Date:  2012-12-16

10.  Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?

Authors:  Oliver Ristow; Carlos Gerngroß; Markus Schwaiger; Bettina Hohlweg-Majert; Melanie Ristow; Steffen Koerdt; Roswitha Schuster; Sven Otto; Christoph Pautke
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-28       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.